Tardive Dyskinesia

Treatment with the new VMAT-2 inhibitors is likely to transform TD management.

Hizentra prevents neuromuscular disability and impairment relapse in patients with CIDP, a rare immune-mediated disorder of the peripheral nerves.

Trial patients' total maximal chorea score improved by 2 points in 8 weeks.

The positive results came from a 3 fixed-dose Phase III trial involving nearly 300 patients.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

Dr. Stanley Caroff, Emeritus Professor CE of Psychiatry at the Philadelphia VA Medical Center, sits down with MD Magazine to explain what tardive dyskinesia is, and why it's so important for psychiatrists to be aware of this side effect in their patients taking antipsychotic medications. This is the conclusion of a two-part conversation.

Results from a six-week study show patients with major depressive disorder treated with brexpiprazole had significantly reduced risk of akathisia and other side effects.

From a pharmacologic perspective metoclopramide is much closer to antipsychotic drugs, in that it is, in part, a blocker of central dopamine receptors.